Helicobacter pylori CAs inhibition.
Enzymes
; 55: 213-241, 2024.
Article
em En
| MEDLINE
| ID: mdl-39222992
ABSTRACT
Infections from Helicobacter pylori (Hp) are endangering Public Health safety worldwide, due to the associated high risk of developing severe diseases, such as peptic ulcer, gastric cancer, diabetes, and cardiovascular diseases. Current therapies are becoming less effective due to the rise of (multi)drug-resistant phenotypes and an urgent need for new antibacterial agents with innovative mechanisms of action is pressing. Among the most promising pharmacological targets, Carbonic Anhydrases (EC 4.2.1.1) from Hp, namely HpαCA and HpßCA, emerged for their high druggability and crucial role in the survival of the pathogen in the host. Thereby, in the last decades, the two isoenzymes were isolated and characterized offering the opportunity to profile their kinetics and test different series of inhibitors.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Inibidores da Anidrase Carbônica
/
Helicobacter pylori
/
Infecções por Helicobacter
/
Antibacterianos
Limite:
Humans
Idioma:
En
Revista:
Enzymes
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Itália
País de publicação:
Estados Unidos